Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibiotics: €13 million to step up EU research on antibiotic resistance

27.11.2003


Today 200 scientists meet in Rome at the EU conference on “The Role of Research in Combating Antibiotic Resistance". It was organised by the European Commission together with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).



Antibiotics, once hailed as a panacea to combat bacterial infections, seem to be more and more ineffective. The human body is responding less and less to antibiotics. New, more dangerous diseases, stubbornly resisting their power, are developing.

The aim of the conference is to identify future research priorities to tackle the problem of anti-bacterial resistance and human health, addressing both basic and clinical research. At the same time, the Commission is announcing that it will invest €6 million to support two major research projects in this field, with a total project budget of €12.6 million from the first call for proposals in the Sixth Research Framework Programme (2002-2006).


One of these projects looks into resistance to the major class of antibiotics in clinical use, while the other project investigates basic molecular mechanisms of resistance. The projects are being negotiated and will start in a few weeks after signing of contracts.

"People trust antibiotics to cure almost any kind of disease: unfortunately, as recent outbreaks of Severe Acute Respiratory Syndrome (SARS) show, this is not the case,” says European Research Commissioner Philippe Busquin.

“Antibiotic resistance is therefore the focus of research within the EU scientific funding programmes. More research for the benefit of patients is needed to make use of the wealth of information provided by more than 140 bacterial genomes known today. We must also make sure that the pharmaceutical industry continues its research into the development of new antibiotics. With more than €100 million invested by the EU over the last four years in this field, we have supported more than 80 research projects on antimicrobial resistance. We will keep up the fight to find innovative answers to this problem.”

Once "wonder drugs" ineffective today

Infectious diseases have the potential, like no other group of diseases, to spread rapidly over large distances in a short time. If no effective tools for treatment and prevention are available, they can dramatically change the lives of people and destabilise societies. The first antibiotic drugs became available in the wake of the Second World War, to save soldiers from deadly wounds. These powerful drugs soon became known as "wonder drugs" and were generously prescribed against minor bacterial infections or even viral infections, against which they have never been effective. Today, we pay the price for this complacency. In a recent Eurobarometer survey, Europeans were asked about their ‘antibiotic habits’: 38% of EU citizens had taken antibiotics in the last 12 months (45% of French and Spaniards but only 22% of Danes) out of whom 93% had a prescription.

Due to overuse and mis-use of these drugs, bacterial resistance to antibiotics is now accelerating at a disturbing rate worldwide. Previously effective antibiotics have lost their powers against a steadily growing list of resistant pathogens. As a result, the arsenal against severe, and often lethal, infectious diseases, like tuberculosis and pneumonia is rapidly diminishing.

Are pharmaceutical companies reluctant to invest in research?

Many pharmaceutical companies have pulled out from investments into research on new antimicrobial drugs. The expected sales revenues are no longer sufficient to make up for the costs linked to the development of these drugs. Many companies have instead refocused their efforts on the more profitable treatments for chronic diseases rather than short-course therapies for infections. This has contributed to making the situation worse.

Research needs

On the other hand, considerable progress has been made in recent years to address these problems thanks to gene technology. Today, more than 140 bacterial genomes are known. However, knowledge of the genetic code of an organism does not in itself generate new drugs. In the light of these developments, plans for how to make the most of European-led research in the fight against antibiotic resistance need to be drawn up. Scientists from various related disciplines will discuss some of the more burning issues at the Antibiotic Resistance conference in Rome from 28-30 November. A report and results will be published after the conference.

New research projects to be launched

Two research projects emerging from the first call for proposals on antibiotic resistance will start their work in early 2004 after signing of contracts. Both aim at a better understanding of fundamental mechanisms of resistance, which will be a necessity for future drug development.

One of these projects will look into how resistance to the major class of antibiotics in clinical use, the ?-lactam antibiotics, arises in some of the most severe hospital and community-spread infections.

The second project also looks at basic molecular mechanisms of resistance, but here the focus is specifically on Streptococcus pneumoniae, for two reasons. The first is that it is the major cause of life-threatening pneumonia, septicaemia and meningitis. The other is that it is also the major cause of milder upper respiratory tract infections and large amounts of antibiotics are therefore consumed every year to treat these infections. The project will study how the bacteria manage to survive, grow and spread in the presence of an antibiotic and what factors determine whether an infection will be mild or severe.

Both projects were selected from the first call for proposals addressing various topics of antimicrobial resistance within the EU Sixth Research Framework Programme and will be presented in more detail in Rome. Three further calls will continue to strengthen the European Research Area on antimicrobial resistance research.

Michael Wappelhorst | alfa
Further information:
http://europa.eu.int/comm/research/conferences/2003/antibiotics

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>